Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

Similar articles for PubMed (Select 23056237)

1.

Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.

Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, Williams SA, Levin S, Black B, Harbut M, Carbone M, Goparaju C, Pass HI.

PLoS One. 2012;7(10):e46091. doi: 10.1371/journal.pone.0046091. Epub 2012 Oct 3.

2.

Evaluation of Salivary Transcriptome Markers for the Early Detection of Oral Squamous Cell Cancer in a Prospective Blinded Trial.

Martin JL, Gottehrer N, Zalesin H, Hoff PT, Shaw M, Clarkson JH, Haan P, Vartanian M, McLeod T, Swanick SM.

Compend Contin Educ Dent. 2015 May;36(5):365-73.

PMID:
26053640
3.

Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.

Creaney J, Dick IM, Robinson BW.

Curr Opin Pulm Med. 2015 Jul;21(4):352-6. doi: 10.1097/MCP.0000000000000167.

PMID:
26016578
4.

A novel mixed integer programming for multi-biomarker panel identification by distinguishing malignant from benign colorectal tumors.

Zou M, Zhang PJ, Wen XY, Chen L, Tian YP, Wang Y.

Methods. 2015 May 15. pii: S1046-2023(15)00204-2. doi: 10.1016/j.ymeth.2015.05.011. [Epub ahead of print]

PMID:
25980368
5.

Two-stage biomarker panel study and estimation allowing early termination for futility.

Zhao S, Zheng Y, Prentice RL, Feng Z.

Biostatistics. 2015 May 11. pii: kxv017. [Epub ahead of print]

PMID:
25964662
6.

Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.

Xu J, Alexander DB, Iigo M, Hamano H, Takahashi S, Yokoyama T, Kato M, Usami I, Tokuyama T, Tsutsumi M, Tamura M, Oguri T, Niimi A, Hayashi Y, Yokoyama Y, Tonegawa K, Fukamachi K, Futakuchi M, Sakai Y, Suzui M, Kamijima M, Hisanaga N, Omori T, Nakae D, Hirose A, Kanno J, Tsuda H.

Cancer Sci. 2015 May 2. doi: 10.1111/cas.12687. [Epub ahead of print]

PMID:
25940505
7.

Discovery of new biomarkers for malignant mesothelioma.

Creaney J, Dick IM, Robinson BW.

Curr Pulmonol Rep. 2015;4(1):15-21. Review.

8.

Serum proteomics in multiple sclerosis disease progression.

Tremlett H, Dai DL, Hollander Z, Kapanen A, Aziz T, Wilson-McManus JE, Tebbutt SJ, Borchers CH, Oger J, Cohen Freue GV.

J Proteomics. 2015 Apr 6;118:2-11. doi: 10.1016/j.jprot.2015.02.018. Epub 2015 Mar 6.

PMID:
25753122
9.

Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.

Røe OD, Stella GM.

Eur Respir Rev. 2015 Mar;24(135):115-31. doi: 10.1183/09059180.00007014. Review.

10.

Validation of a multiprotein plasma classifier to identify benign lung nodules.

Vachani A, Pass HI, Rom WN, Midthun DE, Edell ES, Laviolette M, Li XJ, Fong PY, Hunsucker SW, Hayward C, Mazzone PJ, Madtes DK, Miller YE, Walker MG, Shi J, Kearney P, Fang KC, Massion PP.

J Thorac Oncol. 2015 Apr;10(4):629-37. doi: 10.1097/JTO.0000000000000447.

PMID:
25590604
11.

Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach.

Zamanian-Azodi M, Rezaei-Tavirani M, Hasanzadeh H, Rahmati Rad S, Dalilan S.

Gastroenterol Hepatol Bed Bench. 2015 Winter;8(1):6-18. Review.

12.

Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.

Weber DG, Casjens S, Johnen G, Bryk O, Raiko I, Pesch B, Kollmeier J, Bauer TT, Brüning T.

PLoS One. 2014 Dec 3;9(12):e114483. doi: 10.1371/journal.pone.0114483. eCollection 2014.

13.

Urinary protein biomarkers in the early detection of lung cancer.

Nolen BM, Lomakin A, Marrangoni A, Velikokhatnaya L, Prosser D, Lokshin AE.

Cancer Prev Res (Phila). 2015 Feb;8(2):111-9. doi: 10.1158/1940-6207.CAPR-14-0210. Epub 2014 Nov 21.

PMID:
25416410
14.

Discovery and validation of new potential biomarkers for early detection of colon cancer.

Solé X, Crous-Bou M, Cordero D, Olivares D, Guinó E, Sanz-Pamplona R, Rodriguez-Moranta F, Sanjuan X, de Oca J, Salazar R, Moreno V.

PLoS One. 2014 Sep 12;9(9):e106748. doi: 10.1371/journal.pone.0106748. eCollection 2014.

15.

Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area.

Comar M, Zanotta N, Bonotti A, Tognon M, Negro C, Cristaudo A, Bovenzi M.

PLoS One. 2014 Aug 27;9(8):e104848. doi: 10.1371/journal.pone.0104848. eCollection 2014.

16.

Validation of a blood protein signature for non-small cell lung cancer.

Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM.

Clin Proteomics. 2014 Aug 1;11(1):32. doi: 10.1186/1559-0275-11-32. eCollection 2014.

17.

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.

Sato T, Suzuki Y, Mori T, Maeda M, Abe M, Hino O, Takahashi K.

Cancer Med. 2014 Oct;3(5):1377-84. doi: 10.1002/cam4.297. Epub 2014 Jul 10.

18.

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW.

Thorax. 2014 Oct;69(10):895-902. doi: 10.1136/thoraxjnl-2014-205205. Epub 2014 Jul 18.

19.

Identification of ENO1 as a potential sputum biomarker for early-stage lung cancer by shotgun proteomics.

Yu L, Shen J, Mannoor K, Guarnera M, Jiang F.

Clin Lung Cancer. 2014 Sep;15(5):372-8.e1. doi: 10.1016/j.cllc.2014.05.003. Epub 2014 Jun 3.

PMID:
24984566
20.

[How to conduct public health surveillance? The example of the Observatoire Valaisan de la Santé in Switzerland].

Chiolero A, Paccaud F, Fornerod L.

Sante Publique. 2014 Jan-Feb;26(1):75-84. French.

PMID:
24893517
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk